3 / 39
Volume 4
Nano Research & Applications
ISSN: 2471-9838
Page 62
JOINT EVENT
August 16-18, 2018 | Dublin, Ireland
&
12
th
Edition of International Conference on
Nanopharmaceutics and Advanced Drug Delivery
25
th
Nano Congress for
Future Advancements
Nano Congress 2018
&
Nano Drug Delivery 2018
August 16-18, 2018
CodeSphere: Molecular encoding of nanoparticles for targeted cargo delivery
Keith Henry Moss
DTU National Veterinary Institute, Denmark
C
onventional, untargeted and nonspecific therapies, especially regarding cancer, are commonly associated with a low
therapeutic index due to poor drug efficacy and significant adverse effects. Nanoparticles (NPs) as drug delivery vehicles
represent a promising strategy to overcome such shortfalls. Development in the field of NPs and clinical translation for
therapeutic applications has been limited by technical and regulatory factors. Currently, there are unmet needs in the design,
generation and screening of therapeutic NPs such as a consistent and reproducible synthetic technique capable of up-scaling.
This is, in part, due to the vast array of parameters that each requires optimization. As a result, current strategies to optimize
NPs for therapeutic applications are low-throughput and experimentally time consuming. Nucleic acids and other “hard to
drugify” therapeutic macromolecules have been restricted to highly personalized therapeutic strategies such as chimeric
antigen receptor (CAR) therapy and other adoptive cell therapy (ACT) applications. A breakthrough regarding the field of
CAR T cell therapy would be an
in vivo
administration approach, which could potentially transform an expensive, patient
specific therapy to a generic and widely-available treatment strategy, without the need for patient T-cell gene modification and
expansion ex vivo. Such an innovative approach would utilize NPs to systemically deliver messenger RNA (mRNA), encoding
for CARs targeting surface antigens expressed on cancer cells to T cells. The CodeSphere platform technology represents a
unique strategy to generate and screen for optimized NP/liposome formulations in a high-throughput manner. The novelty in
this proposed technology is the use of a DNA barcode as a unique liposome identifier. This DNA-barcode molecular-encoding
system was previously developed by Bentzen et al., for the large-scale detection of antigen specific T cells and is now being
applied in this new platform. In essence, liposomes will be tagged with a unique DNA barcode encoding for and identifying the
composition. The CodeSphere strategy involves the generation of large, diverse DNA-encoded NP libraries which can then be
screened in a single-tube assay, allowing the simultaneous assessment of thousands of different NP formulations for the most
effective delivery of therapeutic cargo.
Recent Publications
1. Gerber D E (2008) Targeted therapies: a new generation of cancer treatments. American Family Physician. 77(3):311-
319.
2. Jahn A et al. (2010) Microfluidic mixing and the formation of nanoscale lipid vesicles. ACS Nano. 4(4):2077-2087.
3. Abate Daga D and Davila M L (2016) CAR models: Next-generation CAR modifications for enhanced T-cell function.
Molecular Therapy Oncolytics. 3:16014.
4. Bentzen A K et al. (2016) Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with
DNA barcodes. Nat. Biotechnol. 34(10):1037-1045.
Biography
Keith H Moss holds a BSc Degree in Biochemistry and Genetics from the University of Cape Town, RSA and an MSc in Engineering (Biotechnology) from the
Technical University of Denmark (DTU). Currently, as a first year PhD student at DTU, he is engaged in the development of a novel technology platform for the
identification of optimal nanoparticles for therapeutic applications. This project encompasses multiple disciplines and incorporates his interest in human disease
and molecular therapeutics as well as nanotechnology and pharmaceutical drug development.
khmoss@vet.dtu.dkKeith Henry Moss, Nano Res Appl 2018, Volume 4
DOI: 10.21767/2471-9838-C3-015